Board MeetingJun 1, 2026, 08:32 AM
Celcuity to Host Call on Phase 3 VIKTORIA-1 Trial Results June 2
AI Summary
Celcuity Inc. announced it will host a conference call and live webcast on Tuesday, June 2, 2026, to review results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial. The company is a clinical-stage biotechnology firm developing targeted therapies for solid tumors, with gedatolisib as its lead candidate. The VIKTORIA-1 trial has previously reported detailed results for Study 1 (PIK3CA wild-type) and topline results for Study 2 (PIK3CA mutant-type).
Key Highlights
- Celcuity to host conference call and webcast on June 2, 2026.
- Call to review results from Phase 3 VIKTORIA-1 trial's PIK3CA mutant cohort.
- Webcast and call scheduled for 8:00 a.m. EDT / 7:00 a.m. CDT.
- Gedatolisib is the lead therapeutic candidate, a kinase inhibitor.
- VIKTORIA-1 trial evaluated gedatolisib in breast cancer patients.
- VIKTORIA-2 trial is ongoing for advanced breast cancer patients.
- CELC-G-201 trial ongoing for metastatic castration-resistant prostate cancer.
Price Impact
More from CELC